B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy. ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 150 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), participants will receive escalating oral doses of ABBV-525. In part 2 (dose optimization), participants will receive one of two oral doses of ABBV-525, until the recommended phase 2 dose (RP2D) is determined. In part 3 (dose expansion), participants will receive the RP2D oral dose of ABBV-525. The estimated duration of the study is up to 64 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Adverse Events (AE)
Timeframe: Up to Approximately 64 Months
Number of Participants With Dose-Limiting Toxicities (DLT)
Timeframe: Up to Approximately 28 Days
Number of Tumor Lysis Syndrome (TLS)
Timeframe: Up to Approximately 64 Months
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters
Timeframe: Up to Approximately 64 Months
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters
Timeframe: Up to Approximately 64 Months
Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)
Timeframe: Up to Approximately 64 Months
Maximum Observed Plasma Concentration (Cmax) of ABBV-525
Timeframe: Up to 12 Months
Time to Cmax (Tmax) of ABBV-525
Timeframe: Up to 12 Months
Area Under the Plasma Concentration-Time Curve (AUC) of ABBV-525
Timeframe: Up to 12 Months